Hamlin A.,University of California at Davis |
Liu Y.,Dalian Municipal Friendship Hospital |
Nguyen D.V.,University of California at Davis |
Tassone F.,University of California at Davis |
And 3 more authors.
American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics | Year: 2011
This report seeks to establish the prevalence of sleep apnea in patients with the fragile X mental retardation 1 (FMR1) premutation with and without fragile X-associated tremor/ataxia syndrome (FXTAS) and to determine any correlation between CGG repeat and FMR1 mRNA levels with sleep apnea prevalence. Demographic and medical data from 430 (229 males, 201 females) participants were used in this analysis. Participants included premutation carriers with (n=118) and without FXTAS (n=174) as well as controls without the premutation (n=123). Logistic regression models were employed to estimate the odds ratio of sleep apnea relative to controls, adjusted for age and gender, and also to examine potential association with CGG size and FMR1 mRNA expression level. The observed proportion of sleep apnea in premutation carriers with and without FXTAS and controls are 31.4% (37/118), 8.6% (15/174), and 13.8% (17/123), respectively. The adjusted odds of sleep apnea for premutation carriers with FXTAS is about 3.4 times that compared to controls (odds ratio, OR=3.4, 95% confidence interval (CI) 1.8-7.4; P=0.001), and similarly relative to premutation carriers without FXTAS (OR=2.9, 95% CI 1.2-6.9; P=0.014). The risk of sleep apnea was not different between controls and premutation carriers without FXTAS. The presence of sleep apnea is not associated with CGG repeat numbers nor FMR1 mRNA expression level among premutation carriers. Our data supports a higher prevalence and risk of sleep apnea in patients with FXTAS. We recommend that all patients diagnosed with FXTAS be screened for sleep apnea given the negative and perhaps accelerative impact sleep apnea may have on their FXTAS progression. © 2011 Wiley Periodicals, Inc.
Liu Y.,Dalian Municipal Friendship Hospital |
Winarni T.,Diponegoro University |
Zhang L.,University of California at Davis |
Tassone F.,University of California at Davis |
Hagerman R.,University of California at Davis
Clinical Genetics | Year: 2013
The grey zone (GZ; 45-54 CGG repeats in the FMR1 gene) is considered a normal allele; however, several studies have found a high frequency of GZ in movement disordered populations. Here, we describe neurological features of fragile X-associated tremor/ataxia syndrome (FXTAS) in two carriers of GZ alleles, although FXTAS has been defined as occurring only in premutation carriers (55-200 CGG repeats). Both patients had family members who had premutation and were diagnosed with FXTAS. The presence of relatively high GZ alleles with elevated fragile X mental retardation 1 mRNA (FMR1-mRNA) combined with a family history of FXTAS that may represent a facilitating genetic background for FXTAS are the factors that led to the presence of FXTAS in these individuals with a GZ allele. Further research into clinical involvement of GZ alleles is recommended and the definition of FXTAS may require revision. © 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd 84 1 July 2013 10.1111/cge.12026 SHORT REPORT SHORT REPORTS © 2012 John Wiley & Sons A/S.
Ye L.,Dalian Medical University |
Ye L.,Dalian Municipal Friendship Hospital |
Song X.,Dalian Medical University |
Li S.,Dalian Medical University |
And 6 more authors.
Prostate | Year: 2011
Background Prostate cancer is the third most common cancer and the second leading cause of cancer death for males in US. Livin has recently been described as a cancer-associated member of inhibitor of apoptosis proteins family, highly expressed in prostate cancer. Livin gene encodes two splicing variants, termed Livin-α and Livin-β. We hypothesized that deregulation of proliferation could be due in part to Livin expression. Methods Pathological analysis of Livin was performed in 20 prostate cancer tissues and 5 benign prostatic hyperplasia tissues. The expression of Livin isoforms was also investigated by Western blot in prostate cancer cell lines LNCaP and PC3. The role of Livin-α in vitro was further studied. Using Livin-α knockdown and overexpression models, cell cycle analysis, Ki-67 immunocytostaining, and MTT assay were performed respectively. Results Livin expression positive ratio was shown to be 5.4%, 23.6%, 52.4%, 73.4% in benign prostatic hyperplasia, low, medium, and high grade of prostate cancer respectively, and Livin was positively correlated with clinical pathological grades of prostate cancer. Livin-α was expressed in both LNCaP and PC3; meanwhile; Livin-β was only detected in the PC3. Livin-α siRNA not only resulted in G1-S cell cycle arrest, but also strongly correlated with the descended proliferation index and survival rate in LNCaP. In comparison, overexpression of Livin-α resulted in an accelerated S phase entry combined with elevated proliferation index and survival in LNCaP. Conclusions Livin-α may promote cell proliferation by regulating G 1-S cell cycle transition and possibly play an important part in initiation of prostate cancer. © 2010 Wiley-Liss, Inc.
Gao L.,Capital Medical University |
Liu Y.,Dalian Municipal Friendship Hospital |
Li X.,Dalian Municipal Friendship Hospital |
Bai Q.,Dalian Municipal Friendship Hospital |
Liu P.,The Third Peoples Hospital of Dalian
Archives of Gerontology and Geriatrics | Year: 2015
Objective: We investigated possible abnormalities in the retinal nerve fiber layer (RNFL) and macula lutea of patients diagnosed with Alzheimer's disease (AD) and mild cognitive impairment (MCI) and tested for any correlation with the severity of dementia. Methods: A total of 72 subjects, comprising 25 AD patients, 26 MCI patients and 21 healthy individuals (controls) were enrolled in this study. The thickness of the RNFL and volume of the macula lutea was determined using optical coherence tomography (OCT). Results: When compared with controls, we found statistically significant thinning of the RNFL in AD patients at all clock-hour positions except 12:00, and nasal quadrant, 2:00, 3:00 and 4:00. After adjusting several risk factors, the average thickness of the RNFL was reduced in MCI patients compared to AD patients, with specific reductions at inferior quadrant, 5:00 and 6:00. Compared to controls, MCI patients showed a significant decrease in RNFL thickness only in the temporal quadrant, 8:00, 9:00 and 10:00. We found significant reduction in the volume of the macula lutea both in AD and MCI patients. Finally, we could not establish any correlation between patient Mini-Mental State Examination (MMSE) scores (an estimation of the severity of cognitive impairment) and any OCT parameter. Conclusion: Retinal degeneration in AD and MCI patients results in decreased thickness of the RNFL, and reduced macular volume in AD and MCI patients. However, there seems to be no correlation between these changes and the severity of dementia. © 2014 Elsevier Ireland Ltd.
Bai Q.-H.,Dalian Municipal Friendship Hospital |
Miao Y.-Q.,Dalian Municipal Friendship Hospital |
Wang C.-L.,Dalian Municipal Friendship Hospital |
Zhang G.-F.,Dalian Municipal Friendship Hospital
International Eye Science | Year: 2015
AIM: To compare biometry results of IOLMaster and contact ultrasound (US) anterior segment parameters, and to evaluate the calculation accuracy and repeatability of intraocular lens power in both. METHODS: Preoperative measurement of anterior segment parameters were prospectively obtained in 137 eyes of 121 subjects with the IOLMaster compared with the US. Postoperative best corrected visual acuity (BCVA) and the actual diopter were measured. RESULTS: There was an excellent correlation between IOLMaster and US measurements for the ACD (r=0.823, P<0.01) and AL (r=0.996, P<0.01). The mean values of the parameters measured by IOLMaster and US were, respectively, as follows: ACD, 2.94±0.49mm, 2.69±0.51mm; AL, 24.17±1.64mm, 23.81±1.83mm. The mean differences of ACD and AL values between IOLMaster and US measurements were 0.25±0.22mm, 0.36±0.24mm respectively, proved to be statistically significant (P<0.01). With the 95% limits of agreement (LoA) from -0.08~+0.48mm for ACD and from -0.09~+0.69mm for AL. For IOLMaster, the mean prediction error (MPFE) -0.15±0.38D, the mean absolute prediction error (MAFE) was 0.29±0.27D with 96% of the eyes within 1D from the predicted refraction. Applanation ultrasonography after optimisation yielded a greater absolute prediction error than the IOLMaster biometry, 0.41±0.38D with 88% of the eyes within 1D from the predicted refraction. For IOLMaster biometry, the intraobserver variability (SD) was ±25.6μm for AL, ±33.4μm for ACD and ±12.9μm for corneal radius. The coefficients of variation (COV) were 0.11%, 0.52%, and 0.17%, respectively. The interobserver variability (SD) was ±21.5μm for AL, ±29.8μm for ACD and ±15.9μm for corneal radius. The COV were 0.09%, 0.62%, and 0.21%, respectively. CONCLUSION: Partial coherence biometry using the IOLMaster provides the more accurate and reliable anterior segment parameters measurement values. A high degree of agreement between US and IOLMaster is noted. The IOLMaster not only has the advantage of performing noncontact examinations, but also produces various additional data simultaneously and may thus obviate the need for multiple examinations. ©, 2015, International Journal of Ophthalmology (c/o Editorial Office). All right reserved.
Wang L.,Dalian Municipal Friendship Hospital |
Liu J.-W.,Dalian Medical University |
Yu P.-Y.,Dalian Medical University
Chinese Journal of New Drugs | Year: 2013
Objective: To evaluate the efficacy and toxicity of icotinib hydrochloride, and to analyze prognostic factors influencing curative effect in patients with advanced non-small cell lung cancer (NSCLC). Methods: A total of 66 patients with IIIB or IV NSCLC were enrolled in this study from January 2011 to February 2013, and all of these patients had been confirmed by pathology or cytology. Of the patients, 34 were newly diagnosed and received icotinib hydrochloride for the first-line treatment; 16 received icotinib hydrochloride for second-line treatment and 16 for third and more than third-line treatment. Results: Of the 66 patients, 16 had received icotinib hydrochloride for more than one month, and 4 did not tolerate the side events to stop taking the medicine. There was none with complete response, 24 patients had partial response, 24 had stable disease and 14 had progressive disease. The objective response was 38.7%, and the disease control rate was 77.4%. In 7 patients, EGFR was detected and found to be mutant; among them 3 patients had partial response and 4 had stable disease. The total progressive free survival was 7 months. The progressive free survivals after first-line treatment, second-treatment, and third or more than third treatment were 11(1~16.3), 6(0.3~11.5) and 5(1~14.7) months, respectively. The effect of icotinib hydrochloride did not relate to clinical characteristics statistically. Subgroup analysis showed that PFS significantly related to ECOG score, smoking status, pathological types and rash. The main clinically relevant toxicity in 66 patients was rash that occurred in 27 patients including grade I in 23 patients, grade II in 3 patients and grade III in 1 patient. Diarrhea occurred in 12 patients including grade I in 9 patients, grade II in 3 patients and grade III in 3 patients. Other toxic reactions included stomach discomfort, heart discomfort, ALT/AST elevation, vomiting, skin itch, dry skin, pain and anemia. Four patients did not continue the therapy because of adverse events, which included diarrhea (2 patients, one was grade I and one was grade II), vomiting (1 patient, grade I) and cardiac discomfort (1 patient, grade I). Conclusion: Treatment with icotinib hydrochloride shows satisfactory clinical efficacy, and is tolerable for patients with advanced NSCLC. Advanced NSCLC patients with a lower ECOG score or experiencing a skin rash after taking icotinib hydrochloride would achieve better efficacy.
Liu Z.,Dalian Medical University |
Liu Z.,Dalian Municipal Friendship Hospital |
Liu L.,Dalian Medical University |
Li M.,Dalian Medical University |
And 5 more authors.
Pathology | Year: 2011
Aims: Epidermal growth factor receptor (EGFR) and Kirsten- RAS (KRAS) mutations have been identified as predictors of response to EGFR tyrosine kinase inhibitors (TKIs) in nonsmall cell lung cancer. We aimed to screen the mutations of both genes in gastric carcinoma to detect the suitability of EGFR TKIs for patients with gastric carcinoma. Methods: We screened EGFR mutation in exons 19-21 and KRAS mutation in exon 2 in 58 gastric adenocarcinomas from China using high resolution melting analysis (HRMA). Positive samples were confirmed by DNA sequencing. Results: Three EGFR missense mutations (5.2%) and 22 single nucleotide polymorphisms (SNP, Q787Q, 37.9%) were identified. To our knowledge, we report for the first time three mutation patterns of EGFR, Y801C, L858R and G863D, in gastric carcinoma. Two samples with EGFR mutation were mucinous adenocarcinoma. These three samples were collected from male patients aged over 75 years old. The frequency of KRAS mutation was 10.3% (6/58). The exclusiveness of EGFR and KRAS mutations was proven for the first time in gastric cancer. Conclusions: Gastric carcinoma of the mucinous adenocarcinoma type collected from older male patients may harbour EGFR mutations. The small subset of gastric adenocarcinoma patients may respond to EGFR TKIs. © 2011 Royal College of Pathologists of Australasia.
Yu L.,Shandong University |
Li H.-Z.,Shandong University |
Li H.-Z.,Dalian Municipal Friendship Hospital |
Lu S.-M.,Institute of Eye and Otolaryngology |
And 4 more authors.
Journal of Cancer Research and Clinical Oncology | Year: 2011
Purpose: The transcription factor TWIST is an important factor in regulation of the epithelial-mesenchymal transition (EMT), which represents the primary stages during the metastasis of tumors. To identify the role of TWIST in the regulation of metastasis in laryngeal carcinoma Hep-2 cells, we investigated whether the alteration of TWIST has an effect on the Hep-2 cells morphology and whether the alteration of TWIST has an effect on the expression of E-cadherin, N-cadherin as well as the ability of cell motion, migration, and invasion. Methods: Morphological changes of Hep-2 cells that were transfected a mircoRNA against TWIST vector were observed by the reserved microscope. Reverse transcription-polymerase chain reaction was performed in order to examine the mRNA expression of TWIST, E-cadherin, and N-cadherin. Western blotting was performed to examine the protein expression of TWIST, E-cadherin, and N-cadherin. Cell motion ability was examined by Scratch-wound assay. Transwell™ chamber assays were used to determine cell migration and invasion. Results: Transfecting a mircoRNA down-regulated TWIST expression at mRNA and protein levels. Down-regulation of TWIST expression induced morphological changes, such as the inversion of the EMT. Moreover, down-regulation of TWIST expression up-regulated E-cadherin and down-regulated N-cadherin expressions at mRNA and protein levels, respectively. Furthermore, we confirmed that down-regulation of TWIST expression decreased the motion, invasion, and migration ability of the Hep-2 cells. Conclusions: Down-regulation of TWIST expression decreases migration and invasion of laryngeal carcinoma Hep-2 cells by regulation of the E-cadherin, N-cadherin expression. © 2011 Springer-Verlag.
PubMed | Dalian Municipal Friendship Hospital, Washington State University and Dalian Medical University
Type: Journal Article | Journal: Biomedical chromatography : BMC | Year: 2016
The aim of this study was to develop an analytical method for the determination the levels of metabolites of benzo[a]pyrene (B[a]P), 3-hydroxybenzo(a)pyrene (3-OHB[a]P) and (+)-anti-benzo(a)pyrene diol-epoxide [(+)-anti-BPDE, combined with DNA to form adducts], in rat blood and tissues exposed to B[a]P exposure by high-performance liquid chromatography with fluorescence detection (HPLC/FD), and to investigate the usefulness of 3-OHB[a]P and (+)-anti-BPDE as markers of intragastrical exposure to B[a]P in rats. The levels of 3-OH-B[a]P and B[a]P-tetrol I-1 released after acid hydrolysis of (+)-anti-BPDE in the samples were measured by HPLC/FD. The calibration curves were linear (r(2) > 0.9904), and the lower limit of quantification ranged from 0.34 to 0.45 ng/mL for 3-OHB[a]P and from 0.43 to 0.58 ng/mL for (+)-anti-BPDE. The intra- and inter-day stability assay data suggested that the method is accurate and precise. The recoveries of 3-OHB[a]P and (+)-anti-BPDE were in the ranges of 73.6 5.0 to 116.5 6.3% and 73.3 8.5 to 141.2 13.8%, respectively. A positive correlation was found between the concentration of intragastrical B[a]P and the concentrations of 3-OH-B[a]P and (+)-anti-BPDE in the blood and in most of the tissues studied, except for the brain and kidney, which showed no correlation between B[a]P and 3-OHB[a]P and between B[a]P and (+)-anti-BPDE, respectively. A sensitive, reliable and rapid HPLC/FD was developed and validated for analysis of 3-OHB[a]P and (+)-anti-BPDE in rat blood and tissues. There was a positive correlation between the concentration of 3-OHB[a]P or (+)-anti-BPDE in the blood and the concentration of 3-OHB[a]P or (+)-anti-BPDE in the most other tissues examined. The concentration of 3-OHB[a]P or (+)-anti-BPDE in the blood could be used as an indicator of the concentration of 3-OHB[a]P or (+)-anti-BPDE in the other tissues in response to B[a]P exposure. These results demonstrate that 3-OHB[a]P and (+)-anti-BPDE are potential biomarkers of B[a]P exposure, which would also be useful to assess the carcinogenic risks from B[a]P exposure.
PubMed | Hunan University, Dalian Municipal Friendship Hospital, Xiangtan Central Hospital and Dalian Stomatological Hospital
Type: Journal Article | Journal: Apoptosis : an international journal on programmed cell death | Year: 2016
Reperfusion therapy is widely used to treat acute myocardial infarction (AMI). However, further injury to the heart induced by rapidly initiating reperfusion is often encountered in clinical practice. A lack of pharmacological strategies in clinics limits the prognosis of patients with myocardial ischemia-reperfusion injury (MIRI). Dihydromyricetin (DMY) is one of the most abundant components in vine tea, commonly known as the tender stems and leaves of Ampelopsis grossedentata. The aim of this study was to evaluate the cardioprotection of DMY against myocardial ischemia-reperfusion (I/R) injury and to further investigate the underlying mechanism. An I/R injury was induced by left anterior descending coronary artery occlusion in adult male rats in vivo and a hypoxia-reoxygenation (H/R) injury in H9c2 cardiomyocytes in vitro. We found that DMY pretreatment provided significant protection against I/R-induced injury, including enhanced antioxidant capacity and inhibited apoptosis in vivo and in vitro. This effect correlated with the activation of the PI3K/Akt and HIF-1 signaling pathways. Conversely, blocking Akt activation with the PI3K inhibitor LY294002 effectively suppressed the protective effects of DMY against I/R-induced injury. In addition, the PI3K inhibitor partially blocked the effects of DMY on the upregulation of Bcl-2, Bcl-xl, procaspase-3, -8, and -9 protein expression and the downregulation of HIF-1, Bnip3, Bax, Cyt-c, cleaved caspase-3, -8, and -9 protein expression. Collectively, these results showed that DMY decreased the apoptosis and necrosis by I/R treatment, and PI3K/Akt and HIF-1 plays a crucial role in protection during this process. These observations indicate that DMY has the potential to exert cardioprotective effects against I/R injury and the results might be important for the clinical efficacy of AMI treatment.